Regulation of Pandemic Vaccine Rapid Approval Mechanisms in China

1. Introduction

China regulates rapid approval of pandemic vaccines through a combination of pharmaceutical legislation, emergency-use authorisation, clinical-trial oversight, vaccine-specific regulation, and public-health emergency powers. The central objective is to make vaccines available quickly during serious infectious-disease emergencies without abandoning requirements concerning safety, efficacy, quality, and manufacturing standards.

The principal legal framework consists of the Drug Administration Law of the People's Republic of China (2019 revision), the Vaccine Administration Law (2019), the Biosecurity Law (2021), and the relevant drug-registration rules administered by the National Medical Products Administration (NMPA).

China's COVID-19 experience demonstrated that emergency vaccine development can involve overlapping procedures: accelerated clinical development, conditional marketing authorisation, emergency use before ordinary marketing approval, and expedited regulatory review. These mechanisms are legally distinct and should not be treated as interchangeable.

2. Principal Legal Framework

A. Drug Administration Law, 2019

The Drug Administration Law is the foundation of China's pharmaceutical approval system. It empowers the NMPA to supervise drug registration, clinical trials, manufacturing, and marketing.

Article 26 provides a legal basis for conditional approval of drugs intended for serious or life-threatening diseases where clinical-trial data demonstrate clinical value and the remaining evidence can be collected after approval. Conditions may include further studies, time limits, or other obligations imposed by the regulator.

Article 26 should not be interpreted as an unrestricted emergency licence. Conditional approval remains a regulatory decision based on the evidence available and the applicable statutory criteria.

The law also supports accelerated review for medicines urgently needed in response to major public-health emergencies. Such procedures can reduce administrative delays while preserving the regulator's responsibility to assess product quality, safety, and effectiveness.

B. Vaccine Administration Law, 2019

The Vaccine Administration Law establishes stricter controls for vaccines than those generally applicable to ordinary medicines. It governs research, clinical trials, production, distribution, vaccination, and adverse-event monitoring.

Its important principles include:

Stronger quality-management requirements throughout the vaccine lifecycle.

Enhanced supervision of vaccine manufacturers and production facilities.

Traceability of vaccine products and batches.

Monitoring and reporting of suspected adverse reactions.

Legal responsibility for violations of vaccine-safety requirements.

These safeguards remain relevant during pandemics. Emergency conditions may justify expedited procedures, but they do not create a general exemption from vaccine quality and safety obligations.

C. Biosecurity Law, 2021

The Biosecurity Law strengthens China's governance of biological risks, infectious diseases, biotechnology activities, and public-health emergencies. It provides a broader institutional framework for preparedness, risk prevention, and coordination between relevant authorities.

Its relevance to vaccine approval is principally systemic: it supports emergency preparedness and the management of biological threats, while product-specific authorisation continues to depend on pharmaceutical and vaccine legislation.

3. Main Rapid Approval Mechanisms

A. Priority review and approval

Article 19 of the Vaccine Administration Law requires priority evaluation and approval for vaccines urgently needed for disease prevention and control and for innovative vaccines. This mechanism accelerates regulatory processing but does not itself authorise marketing or emergency use.

B. Conditional marketing authorisation

Under Article 20, the NMPA may conditionally approve a vaccine needed to respond to a major public-health emergency if an assessment establishes that its benefits outweigh its risks.

The authorisation holder must fulfil specified post-approval obligations, including additional research and submission of further evidence. Failure to meet the requirements may lead to regulatory action, including withdrawal of the registration certificate.

C. Emergency use authorisation

Article 20 separately permits emergency use when an exceptionally serious public-health emergency or another emergency seriously threatens public health. The National Health Commission recommends urgent use according to disease-control needs, and the NMPA organises an assessment before authorisation.

Emergency use is restricted to a specified scope and period. Unlike conditional marketing authorisation, it is not equivalent to ordinary marketing approval and should be understood as a distinct emergency pathway.

Ministry of Justice of China

+1

D. Manufacturing and batch-release controls

Article 28 permits the NMPA to exempt urgently needed vaccines from ordinary batch-release requirements in qualifying circumstances. This is a specific statutory flexibility, not a blanket exemption for pandemic vaccines.

Manufacturing authorisation, quality controls, traceability, and applicable safety obligations continue to matter. Article 57 also requires post-marketing risk management and further studies where required.

4. Relevant Cases and Regulatory Precedents

Directly reported Chinese court judgments interpreting Article 20's pandemic-vaccine authorisation mechanism are limited. Consequently, the most useful precedents are regulatory decisions demonstrating how the statutory framework operated.

Case 1: Sinopharm Wuhan COVID-19 vaccine, 2021

On 25 February 2021, the NMPA conditionally approved the inactivated COVID-19 vaccine developed by the Wuhan Institute of Biological Products, administered by Sinopharm. The decision was announced on 27 February 2021.

The regulator used emergency review procedures and required the manufacturer to continue research, fulfil approval conditions, and submit subsequent research results.

National Medical Products Administration

Legal significance: This decision illustrates conditional marketing authorisation as a means of accelerating access while requiring additional evidence. It is an administrative regulatory precedent, not a judicial case establishing binding court doctrine.

Case 2: Sinopharm Beijing COVID-19 vaccine, 2020

China conditionally approved Sinopharm's Beijing Institute-developed inactivated COVID-19 vaccine in December 2020. The decision followed clinical development and regulatory assessment during the pandemic.

Legal significance: The decision illustrates that accelerated approval does not mean approval without supporting evidence. The conditional route allows a regulator to act on an available evidentiary record while imposing continuing obligations.

Case 3: COVID-19 vaccine emergency use, 2020

China began emergency use of selected COVID-19 vaccine candidates in 2020 before ordinary marketing authorisation. The programme was subsequently governed by the statutory distinction between emergency use and conditional registration approval.

Legal significance: This experience demonstrates why emergency use and conditional marketing authorisation must be analysed separately. The former permits restricted urgent use; the latter grants conditional marketing approval under the applicable registration framework.

These are regulatory precedents rather than reported court cases. It would be misleading to describe them as judicial holdings.

5. Accountability and Legal Challenges

Rapid approval creates several legal and ethical concerns:

Evidence and transparency: Regulators must assess the available safety, efficacy, and quality evidence.

Clinical-trial ethics: Article 18 requires written informed consent for vaccine clinical trials.

Post-authorisation monitoring: Manufacturers must monitor adverse reactions and fulfil further-study obligations.

Manufacturing accountability: Defective production, falsified data, or non-compliance may trigger administrative or other legal liability.

Public-health proportionality: Emergency action must remain within the scope and period authorised by law.

6. Conclusion

China's pandemic vaccine rapid-approval framework rests principally on Articles 19 and 20 of the Vaccine Administration Law, supported by the Drug Administration Law and associated regulatory procedures. Its central mechanisms are priority review, conditional marketing authorisation, emergency use authorisation, and limited flexibility in batch release.

The COVID-19 vaccine decisions demonstrate that accelerated approval is a structured regulatory process, not a suspension of all safeguards. Although these decisions provide valuable administrative precedents, they should not be confused with judicial case law.